The short version
4 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Imatinib Mesylate
imatinib · IMATINIB MESYLATE 100 mg/1 · Tablet, Film Coated · Oral · Golden State Medical Supply, Inc.
NDC 51407-0269-90 · 90 TABLET, FILM COATED in 1 BOTTLE, PLASTIC · ANDA · View full market →
One drug, every price
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
ⓘ How this was built
Data sources
- CMS NADAC (pharmacy acquisition, weekly)
- CMS Part B ASP quarterly payment limits
- CMS Maximum Fair Prices (IRA negotiated, NDC-level)
- Medicare Part D Spending by Drug (data.cms.gov, name-matched)
- VA FSS / Big4 federal contract prices (va.gov, twice monthly)
- ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
- California SB-17 WAC filings (list price, per package)
Method
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
- Part D plans paid (avg)$33.39per dosage unitgross, before rebates — matched by drug name · 2024
- Federal contracts pay (FSS)$0.7846per unitGolden State Medical Supply, Inc. · Feb 27, 2022
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.1%chance of a new FDA shortage posting for imatinib (oral solid) in the next 90 days
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $1,270.90 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- ANDA204644
- TE code
- AB
- Approval date
- Jun 21, 2017
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of imatinib (Tablet, Film Coated)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Golden State Medical Supply, Inc. | IMATINIB MESYLATE 100 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Golden State Medical Supply, Inc. | IMATINIB MESYLATE 400 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Mylan Institutional Inc | IMATINIB MESYLATE 400 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Mylan Institutional Inc | IMATINIB MESYLATE 100 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Mylan Pharmaceuticals Inc. | IMATINIB MESYLATE 100 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Mylan Pharmaceuticals Inc. | IMATINIB MESYLATE 400 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Safecor Health, LLC | IMATINIB MESYLATE 100 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Safecor Health, LLC | IMATINIB MESYLATE 400 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Imatinib Mesylate — NDC 51407-0269-90," retrieved September 3, 2026, https://drugdashboards.com/drug/51407026990.
Free to cite with attribution — see how the data is put together.